The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.
Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic.
To be considered for the study you must meet the following criteria:
- Metastatic prostate cancer with demonstrated resistance to standard ADT
- eGFR ≥ 40 mL/min/1.73 m2
- Prostate cancer with significant neuroendocrine or sarcomatoid component
- Chemotherapy within previous two months
- External beam radiotherapy within previous two months
The Enzalutamide-Enhanced Imaging study – is a Phase II study comparing the expression of prostate-specific membrane antigen (PSMA), before and after treatment with enzalutamide (Xtandi®)1, using positron emission tomography (PET). Forty Australian men with progressive metastatic castrate-resistant prostate cancer (mCRPC) who are about to receive second-line androgen-deprivation therapy with enzalutamide will be enrolled. Enzalutamide is believed to increase PSMA expression in some patients with prostate cancer and the goal of ENHANCING is to quantify this increase, to evaluate the potential of combining enzalutamide with PSMA-targeting radiopharmaceuticals for prostate cancer treatment.